Besides, GRN-specific neutralizing antibody can repress the vascular endothelial growth factor levels and inhibit angiogenesis in HCC, which indicates that GRN is the potential target for HCC therapy [32]. Here, VEGFA is linked to hepatocellular carcinoma.